Shares of Palisade Bio, Inc. (NASDAQ:PALI - Get Free Report) have been given an average recommendation of "Buy" by the ten ratings firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $9.00.
A number of equities research analysts recently commented on the stock. Raymond James Financial started coverage on shares of Palisade Bio in a research note on Thursday, October 8th. They issued an "outperform" rating and a $6.00 price objective on the stock. Oppenheimer restated an "outperform" rating on shares of Palisade Bio in a research report on Wednesday, October 21st. Wall Street Zen downgraded shares of Palisade Bio from a "sell" rating to a "strong sell" rating in a report on Saturday, November 14th. HC Wainwright lowered their price target on shares of Palisade Bio to $5.00 and set a "buy" rating on the stock in a research report on Wednesday, November 11th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Palisade Bio in a research note on Monday, October 12th.
Check Out Our Latest Stock Analysis on Palisade Bio
Insiders Place Their Bets
In other news, Director Robert Baltera bought 50,000 shares of Palisade Bio stock in a transaction on Tuesday, November 17th. The shares were bought at an average cost of $1.01 per share, for a total transaction of $50,500.00. Following the acquisition, the director owned 511,904 shares in the company, valued at approximately $517,023.04. This trade represents a 10.82% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.07% of the company's stock.
Institutional Investors Weigh In On Palisade Bio
Hedge funds and other institutional investors have recently modified their holdings of the company. Jupiter Topco LLC bought a new stake in Palisade Bio in the 2nd quarter valued at about $22,394,000. BlackRock Inc. bought a new position in Palisade Bio in the 2nd quarter worth about $21,813,000. Artia Global Partners LP bought a new position in Palisade Bio in the 2nd quarter worth about $4,164,000. Soleus Capital Management L.P. grew its position in Palisade Bio by 14.8% in the 3rd quarter. Soleus Capital Management L.P. now owns 14,996,154 shares of the company's stock worth $20,245,000 after purchasing an additional 1,932,467 shares during the last quarter. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Palisade Bio in the second quarter valued at approximately $3,609,000. 11.79% of the stock is currently owned by hedge funds and other institutional investors.
Palisade Bio Stock Down 9.2%
NASDAQ PALI opened at $0.84 on Friday. The firm has a market cap of $150.58 million, a P/E ratio of -1.75 and a beta of 1.61. Palisade Bio has a 52-week low of $0.84 and a 52-week high of $2.85. The business's 50-day moving average price is $1.37 and its 200 day moving average price is $1.80.
Palisade Bio (NASDAQ:PALI - Get Free Report) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.01). As a group, analysts anticipate that Palisade Bio will post -0.24 earnings per share for the current year.
Palisade Bio Company Profile
(
Get Free Report)
Palisade Bio is a clinical-stage biopharmaceutical company developing therapies for gastrointestinal diseases, with a focus on oral treatments for inflammatory bowel conditions. Its pipeline includes PALI-2108, an investigational, gut-targeted PDE4 inhibitor being developed for ulcerative colitis and fibrostenotic Crohn's disease. The company has also developed LB1148, an investigational serine protease inhibitor studied for its potential to support bowel function and reduce complications after abdominal surgery.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Palisade Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Palisade Bio wasn't on the list.
While Palisade Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.